Open AccessTicagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2‐Hour Infusion in High‐Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention
Author(s) -
Marian Moazez J.,
Alli Oluseun,
Al Solaiman Firas,
Brott Brigitta C.,
Sasse Mark,
Leesar Tara,
Prabhu Sumanth D.,
Leesar Massoud A.
Publication year - 2017
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.117.005562
Subject(s) - eptifibatide , medicine , ticagrelor , percutaneous coronary intervention , bolus (digestion) , p2y12 , tirofiban , cardiology , myocardial infarction , anesthesia , platelet aggregation inhibitor , platelet
In patients with non-ST-segment elevation acute coronary syndromes, inhibition of platelet aggregation (IPA) with a potent P2Y 12 inhibitor, ticagrelor, was inferior to tirofiban infusion at 2 hours, indicating that glycoprotein IIb/IIIa inhibitors are still needed. Ticagrelor and eptifibatide bolus only may maximally inhibit platelet aggregation and decrease bleeding, but IPA with ticagrelor and eptifibatide bolus versus 2-hour infusion is unknown.